Sucampo Pharmaceuticals Inc

Sucampo Pharmaceuticals — Investor Presentation (June 2013)

13 slides from Sucampo Pharmaceuticals's investor presentation, Jun 26, 2013

  1. Slide 1: Sucampo: Leader in Gastroenterology with Three Approved Indications for AMITIZA

    CIC Globally, CIC affects ~14%−16%2,3 and CIC accounts for 92,000 hospitalizations/yr in US4 IBS-C IBS-C affects ~5% of adult population globally5 Patients with IBS consume >50% more healthcare resources than those without IBS6 and the direct and indirect costs of IBS care in the US equal $20 billio

  2. Slide 2: AMITIZA US: OIC approval and strong YOY growth

    OIC indication approved in April 2013 Priority review for first and only medicine for the treatment of OIC in adults with chronic, non-cancer pain $10M milestone payment received Partner Takeda’s reps began selling week of May 13 Strategy to build awareness that AMITIZA is the first and only medicin

  3. Slide 3: Near-Term Strategy to Grow AMITIZA

    Near-Term Strategy to Grow AMITIZA Target Goal PCPs who already write AMITIZA +OIC Pain Specialists Gis Target Goal PCP Non-Writers +CIC +IBS-C +OIC

  4. Slide 4: Competitive Landscape in OIC

    Competitive Landscape in OIC Bevenopran Adolor/Cubist Phase 3 Phase 2 Marketed Naloxone S.L.A. Pharma AG Naloxegol AstraZeneca/Nektar Relistor (PO) Progenics/Salix TD1211 Theravance/ GlaxoSmithKline AMITIZA Sucampo/Takeda Filed Relistor (SC) Progenics/Salix EXPECT NO MARKET CHALLENGE FOR AMITIZA USE

  5. Slide 5: AMITIZA Globally

    ON0-3849 Ono Pharmaceutical S-297995 Shionogi First-ever prescription medicine approved for chronic constipation All launch metrics have been surpassed: revenue and patient numbers tracking above expectation Sucampo recorded $2.2M of product sales revenue in Q1, double our internal forecast AMITIZA

  6. Slide 6: Sucampo: Emerging Player in Ophthalmics

    Glaucoma is age-related and the second leading cause of bilateral blindness worldwide; will affect an estimated 79.6M people worldwide by 202013 Reduction in intra-ocular pressure (IOP) is currently the only modifiable risk factor for patients with glaucoma and ocular hypertension13 Direct cost (hea

  7. Slide 7: Unique Considerations for Glaucoma Treatment in Elderly Patients

    More than 11M Americans are ≥ 80 years of age22 Age is an independent risk factor for glaucoma18 Elderly patients generally have greater susceptibility to the systemic adverse effects of glaucoma medications23 9.2M 11.2M 12.8M 18.9M 27.6M 32.5M 0 10 20 30 40 2000 2010 2020 2030 2040 2050 Population

  8. Slide 8: RESCULA Launch Update

    Positive feedback and significant progress Efforts focused on ophthalmologists and optometrists More than 22,000 calls have already been made Over 78,000 samples have been shipped Expect sales to increase in 2H Aggressively pursuing managed care coverage for RESCULA Over 100 face to face meetings wi

  9. Slide 9: Key Facts

    RESCULA Launch Update Trading Symbol SCMP (NASDAQ) Corporate Headquarters Bethesda, MD Stock Price (06-24-13), 52-Week Range $6.55, $10.48 to $3.78 Shares Outstanding (06-24-13) 42.3M (1 class of common stock) Daily Volume (90-day average) 242,322 Market Capitalization (06-24-13) $276.9M Debt (03-31

  10. Slide 10: Terms of Sucampo's AMITIZA Agreements

    Takeda Agreement Takeda shall promote, market, and sell AMITIZA in US and Canada Sucampo’s tiered royalty rate: 18%−26% of annual net sales Sucampo earned $20M in upfront and $130M in development milestone payments as of 03/31/13 Sucampo received $10M milestone payment following the first OIC sale S

  11. Slide 11: Issued Lubiprostone Patents (cont'd)

    Issued Lubiprostone Patents (cont’d) Japanese Patent No. Expires Type of Patent 4,332,316 2023 Composition of matter (drug substance and drug product) 4,332,353 2022 Therapeutic use (treating OIC) 4,684,334 2023 Therapeutic use (treating constipation) 4,783,794 2028 Composition of matter (drug produ

  12. Slide 12: References

    1. Sucampo data on file. 2. Suares et al. Am J Gastroenterol. 2011 3. Kantar Health Epi database http://epidb.khapps.jp 4. Lembo et al. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. 2010 5. Saito et al. Am J Gastroenterol. 2002 6. Hulisz D. J Manag Care Pharm. 2004 7. Salmoirago-Blot

  13. Slide 13: References (cont'd)

    22. American Academy of Ophthalmology Glaucoma Basic and Clinical Science Course 2012-2013 23. Kaiserman I et al. Topical beta blockers in asthmatic patients-is it safe? Curr Eye Res. 2009 Jul;34(7):517-22. 24. Based on US Census Bureau data from May 2010 and November 2011 The Older Population: 2010

Sucampo Pharmaceuticals — Investor Presentation (June 2013) on 6ix